a day ago
Lexeo Therapeutics price target lowered to $15 from $20 at Chardan
Chardan lowered the firm's price target on Lexeo Therapeutics (LXEO) to $15 from $20 and keeps a Buy rating on the shares after the company reported Q2 results and affirmed upcoming catalysts for its LX2006 and LX2020 programs. The firm said it awaits further visibility on focus and strategy, but thinks a non-viral approach could be 'quite interesting.' Chardan added that it updated its Lexeo model for Q2 financials, including dilution from the May offering.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
